Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (with DAC), a long-acting analog of GH-releasing hormone, in healthy adults

What Was Tested

The paper reports a study of GHRH (Growth Hormone-Releasing Hormone) and CJC-1295 with DAC, published as a randomized controlled trial.

Therapeutic use of GHRH to enhance GH secretion is limited by its short duration of action.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got GHRH (Growth Hormone-Releasing Hormone) and who got the comparison, which limits bias.

As a double-blind GHRH (Growth Hormone-Releasing Hormone) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with GHRH (Growth Hormone-Releasing Hormone) could be set against what happens without it.

The study was performed at two investigational sites.

What Was Measured

Topics PubMed links to this paper include Growth Hormone-Releasing Hormone, Human Growth Hormone, Insulin-Like Growth Factor I and Peptide Fragments.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of GHRH (Growth Hormone-Releasing Hormone) and CJC-1295 with DAC.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2006 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page and the CJC-1295 with DAC compound page, all human trials.